Brain metastasis from calcitonin-negative medullary thyroid carcinoma

Introduction: Medullary thyroid cancer (MTC) is a primary neuroendocrine tumor derived from parafollicular cells or C-cells of the thyroid gland. It accounts for 1% to 10% of all thyroid cancers and is the second most aggressive thyroid cancer after undifferentiated thyroid carcinoma. Serum calciton...

Full description

Saved in:
Bibliographic Details
Published in:Annales d'endocrinologie 2022-08, Vol.83 (4), p.258-260
Main Authors: Baptista, Patrícia Ferreira, Fonseca, Liliana Cecília Martins, de Carvalho, André Filipe Couto, Silva, Sara Neves Vieira da, Freitas, Cláudia Raquel Oliveira
Format: Article
Language:English
Subjects:
brain metastasis
calcitonin-negative
Medullary thyroid carcinoma
neuroendocrine
thyroid cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Medullary thyroid cancer (MTC) is a primary neuroendocrine tumor derived from parafollicular cells or C-cells of the thyroid gland. It accounts for 1% to 10% of all thyroid cancers and is the second most aggressive thyroid cancer after undifferentiated thyroid carcinoma. Serum calcitonin and carcinoembryonic antigen (CEA) concentrations are widely used as biomarkers to facilitate diagnosis and follow-up. However, in rare cases, serum levels of calcitonin or CEA can be normal. Case presentation: We report the case of a 64-year-old male patient with MTC who presented brain metastasis and normal preoperative serum levels of calcitonin and CEA. The patient underwent total thyroidectomy with central compartment lymph-node dissection, resection of the single brain metastasis, and adjuvant holo-cranial radiotherapy. At 30 months’ follow-up, he maintained normal serum calcitonin and CEA levels with increased procalcitonin levels. Conclusions: We describe a rare case of “calcitonin-negative” MTC with brain metastasis. The pathophysiology underlying normal serum levels of calcitonin in MTC is still not clearly understood. The lack of effective serum biomarkers for these patients makes diagnosis and treatment challenging.
ISSN:0003-4266
DOI:10.1016/j.ando.2022.04.015